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Introduction: The aim of this review is to evaluate the
effectiveness of educational interventions on improving
the control of blood pressure in patients with
hypertension.
Methods: Randomised controlled trials including
patients over 18 years of age, regardless of sex and
ethnicity, with a diagnosis of hypertension (either
treated or not treated with antihypertensive
medications) will be assessed in our analysis. We will
electronically search four databases: MEDLINE,
CINAHL, PEDro and ScienceDirect. There will be no
language restrictions in the search for studies. The
data will be extracted independently by two authors
using predefined criteria. Disagreements will be
resolved between the authors. The risk of bias will be
assessed using the Cochrane risk of bias tool. After
searching and screening of the studies, we will run a
meta-analysis of the included randomised controlled
trials. We will summarise the results as risk ratio for
dichotomous data and mean differences for continuous
data.
Ethics and dissemination: The review will be
published in a journal. The findings from the review
will also be disseminated electronically and at
conference presentations.
Trial registration number: PROSPERO
CRD4201401071.
INTRODUCTION
Description of the condition
Hypertension is a major health problem
worldwide, and is estimated to cause more
than 13% of deaths annually.1 It is a multifac-
torial clinical condition characterised by
high and sustained levels of blood pressure.2
It is one of the most important public health
problems in the world and an important
modifiable risk factor for the development of
cardiovascular diseases. Adoption of healthy
lifestyles by all individuals is critical for the
prevention of high blood pressure and is an
indispensable part of the management of
those with hypertension.3 Uncontrolled
hypertension is associated with high risk for
development of heart disease, stroke, chronic
kidney disease, retinopathy and peripheral
vascular disease.
A recent epidemiological worldwide study
estimated that high blood pressure causes
approximately 7.6 million premature deaths
(54% for stroke and 47% for ischaemic heart
disease).4 A recent systematic review report-
ing data from studies in 35 different coun-
tries between the years 2003 and 2008
demonstrated an overall prevalence of 37.8%
for men and 32.1% for women.5
Owing to the fact that the prevalence of
hypertension increases with age,6 the man-
agement of hypertension, and the preven-
tion and treatment of major complications
related to hypertension, will continue to be a
global challenge for healthcare professionals.
Description of the intervention
Hypertension is a condition almost entirely
managed by the primary care team including
a variety of health professionals such as physi-
cians, nurses, pharmacists and other allied
healthcare professionals such as physiothera-
pists, who frequently work in cardiac rehabili-
tation. All professionals can potentially play
an important role in lowering blood pres-
sure. It is important that patients understand
the benefits of blood pressure lowering,
Strengths and limitations of this study
This systematic review will help:
▪ Clinicians to make decisions in clinical practice;
▪ Patients to better understand their conditions;
▪ To heighten awareness about disease progres-
sion and complication.
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which include a reduction in many complications such
as stroke (35–40%), heart attack (20–25%) and heart
failure (over 50%).3 The majority of patients will require
a combination of antihypertensive drugs to reach target
blood pressure.
A previous study demonstrated that educational inter-
ventions increased participants’ levels of knowledge
about hypertension and had a positive influence on
their beliefs about medicines.7 Educational interventions
can also create opportunities for patients to better
understand their conditions and the role of therapies, as
well as heighten awareness about disease progression
and complications. Through patient education, miscon-
ceptions that patients have about their therapy can be
clarified. This can influence adherence to therapy,8 and
may therefore potentially lead to improved blood pres-
sure control.
How the intervention might work
Different health professionals have become more
involved in delivering interventions to their patients with
the objective of preventing complications caused by
high blood pressure. Patient expectations have a signifi-
cant effect on the treatment patients get from their
doctor or other health professional.9 Many previous
trials in blood pressure control have used educational
interventions on patients, physicians, or both, in an
attempt to improve blood pressure control.
Educational interventions can positively modify
patients’ beliefs, which in turn can lead to a change in
patient behaviour, such as improvement in adherence to
a therapy proposed by the healthcare professional8 and
a possible effect on variables related to the disease, such
as blood pressure levels. This may also affect, in the long
term, progression of the disease and the prevalence of
associated conditions related to hypertension, such as
heart attacks and stroke.
Why it is important to present this review
Owing to the high morbidity and mortality caused by
hypertension, and the global scale of this important
public health issue, it is important to continue to investi-
gate interventions that can improve blood pressure
control. It is striking that blood pressure goals continue
to be achieved in only 25–40% of the patients who take
antihypertensive drug treatment,3 10 which is a statistic
that has remained unchanged for the past 40 years.11
A recent Cochrane review demonstrated that there are
many categories of interventions that singly or in unison
have the potential to reduce blood pressure in patients
with hypertension.12 In this review, educational interven-
tions directed to patient and physician were examined;
however, the focus of the review and protocol was not
the educational intervention alone. Educational inter-
ventions, whether delivered to health professionals or
patients, did not appear to be associated with large net
reductions in blood pressure, but were recommended as
an adjunct additional therapy along with other types of
interventions.
Owing to the fact that there has been an increasing
number of recent studies showing the importance of
prevention in patients with hypertension,13–15 our review
will determine the current evidence of the effects of
educational interventions to improve control of blood
pressure in patients with hypertension, potentially updat-
ing the recommendation for clinical practice.
METHODS AND ANALYSIS
Criteria for considering studies for the review
Types of studies
We plan to include randomised clinical trials (RCTs)
that have evaluated the effects of different models of
educational interventions with the overall aim of improv-
ing blood pressure control in patients with hypertension,
irrespective of language. The review will include RCTs
where educational interventions used as the main or
adjunct treatment were compared to no educational
interventions or different types of educational strategies.
We will exclude studies that use educational interven-
tions not intended to improve blood pressure control.
Types of participants
We will include studies that have participants over
18 years of age, regardless of sex and ethnicity, with a
diagnosis of hypertension either treated or not treated
with antihypertensive medications in a primary care, out-
patient or community setting.
Types of interventions
The intervention of interest will include all educational
intervention strategies designed to improve the control
of blood pressure in patients with hypertension (eg, edu-
cational interventions direct to the patient; educational
interventions direct to the health professional).
Comparators will be any educational intervention used
as the main or adjunct treatment to improve the control
of blood pressure compared with either no educational
interventions or different types of educational strategies
aimed to improve blood pressure control.
Types of outcome assessments
The primary outcome of this review will be any changes
in mean systolic blood pressure (SBP) and/or mean dia-
stolic blood pressure (DBP) in any care setting as well as
the number of patients under blood pressure (BP)
control or proportion of controlled BP defined by each
randomised trial’s investigators. The secondary outcomes
will be: number of hospitalisations during treatment (eg,
increase of BP) or mortality from cardiovascular disease
as adverse events; the costs and cost effectiveness of inter-
ventions; and the adherence to intervention (dropout
rate) or adherence to medication; the outcome quality of
life will be measured using standardised generic
questionnaire.
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Search methods for identification of studies
Electronic searches
We will electronically search the following databases:
MEDLINE, CINAHL, PEDro and ScienceDirect, without
any language restrictions (in case of studies in a lan-
guage other than English, we will contact companies
specialised in translation). The search strategy will be
developed after discussion among reviewers, according
to the guidance of the Cochrane handbook.16 The
MEDLINE search strategy will be translated into the
other databases using appropriate controlled vocabulary
as applicable for each database.
Other sources
The bibliographies of all retrieved and relevant publica-
tions identified by the above strategies will be searched
for further studies. In addition, we will search the WHO
International Clinical Trials Registry Platform (ICTRP;
http://apps.who.int/trialsearch/). We will attempt to
contact researchers to obtain additional information
when needed.
Data collection and analysis
Selection of studies
Before the selection of studies, a procedure for screen-
ing will be developed by discussion among all the
reviewers. We will extract data into Review Manager 5.317
and summarise details using a standard data extraction
sheet. Two reviewers (CR and VR) will independently
assess the titles and abstracts of the studies identified
from the search strategy against the inclusion criteria.
Full versions of articles that appear to fulfil the inclusion
criteria will be obtained for further assessment. Another
review author (IL) will evaluate any discrepancies, if
necessary, and will advise in case of disagreement. We
will record all reasons for exclusion and exclude studies
that do not use educational interventional to improve
blood pressure control.
Data extraction and management
Two review authors (CR and VR), working independ-
ently, will extract data and summarise details of trials
using a standard data extraction sheet. According to
methods described in the Cochrane Handbook for
Systematic Reviews of Interventions,18 the extraction
sheet includes information such as study design, meth-
odology, participants, interventions, duration of treat-
ment, outcomes, conclusions and potential sources of
bias. We will resolve any discrepancies by discussion with
a third review author (IL). If studies report more than
one outcome time (eg, 6 and 12 months), data concern-
ing the longest follow-up will be extracted. Where data
are found to be missing, we will contact the correspond-
ing author of the study to request the missing data or to
clarify study details.
Assessment of risk of bias in included studies
For assessment of study quality and reporting bias, two
reviewers (CR and VR) will independently assess the risk
of bias, using the Cochrane collaboration’s tool for asses-
sing risk of bias of the included trials,19 which is com-
posed of six domains of a trial, such as random
sequence generation (selection bias), allocation conceal-
ment (selection bias), blinding (performance bias and
detection bias), incomplete outcome data (attrition
bias), selective outcome reporting (reporting bias) and
other bias. After assessing all the domains, the reviewers
will summarise the assessments and categorise the
included trials into three levels of bias: low, unclear and
high risk of bias. We will resolve any disagreements by
discussion with a third author (IL).
Measures of treatment effect
We will present the effects on blood pressure between
interventions at follow-up (systolic and diastolic blood
pressure) according to the educational interventions
proposed in each study. We will present the outcome
results for each trial with 95% CIs. Continuous outcomes
(such as changes in systolic and diastolic blood pressure)
will be expressed and calculated as mean difference
(MD), and overall effect size between intervention and
control groups. We will use Relative Risk (RR) or OR
depending on measurements indices in individual
studies for other primary and secondary outcomes.
Dealing with missing data
In the case of missing data, we will contact the original
investigators to request missing data whenever possible.
If the trial does not specify a participant group number
prior to dropout, we will present only complete case ana-
lysis for primary and secondary outcomes.
Assessment of heterogeneity
Whenever studies appear to be similar in terms of par-
ticipant characteristics (established hypertensive, people
with diabetes or other chronic disease), intervention
type, duration and outcome type, we will pool data using
meta-analysis (using RevMan 5.3). We will test statistical
heterogeneity using the χ2 test (considering a value of
p<0.1 to indicate heterogeneity) and estimate the
amount of heterogeneity using the I2 statistic.20 If I2 is
over 50%, indicating a high level of heterogeneity, data
will not be pooled. In the absence of clinical and statis-
tical heterogeneity we will use a fixed-effect model.
Assessment of reporting biases
We will present the overall risk of bias (random sequence
generation, allocation concealment, blinding of partici-
pants and personnel, blinding of outcome assessment,
incomplete outcome data, selective reporting) in a risk of
bias summary table per study. If sufficient studies (more
than 10) are identified, an attempt will be made to
examine for publication bias using a funnel plot, as
described in the Cochrane Handbook for Systematic
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Reviews of Interventions.21 If asymmetry is present, we
will explore possible causes including publication bias,
poor methodological quality and true heterogeneity.
Data synthesis
We will present a narrative overview of the combined
studies with meta-analysis of outcome data using the soft-
ware Review Manager V.5.3 where appropriate.
We will include cluster-randomised trials in the ana-
lysis. For cluster-randomised trials, we will adjust results
when the unit of analysis in the trial is presented as the
total number of individual participants instead of
number of clusters. Results will be adjusted using the
mean cluster size and intracluster correlation coeffi-
cient.22 For meta-analysis, data will be combined to indi-
vidually randomised trials using the generic
inverse-variance method as described in Chapter 16.3 of
the Cochrane Handbook for Systematic Reviews of
Interventions.22
The decision to include studies in a meta-analysis will
depend on the availability of treatment effect data and
assessment of heterogeneity. Intervention effects will be
calculated as RRs with 95% CIs for dichotomous data.
For continuous data, we will calculate mean differences
with 95% CIs using a conservative fixed-effects
meta-analysis model in the absence of significant hetero-
geneity (p>0.05 or I2 <50%). If there is a high level of
heterogeneity (I2 >50%), we will not pool data and we
will perform sensitivity analysis of data.
Subgroup analysis
Subgroup analysis will be carried out according to the
following variables: age and gender of participants, and
the professional delivering the intervention (eg, nurse).
Sensitivity analysis
If sufficient trials are identified, we plan to conduct sen-
sitivity analyses in order to explore the influence on the
results of the following factor: assessor blinding (high
risk of bias vs low risk of bias). We will restrict analyses to
studies at low risk of bias.
Ethics and dissemination
This systematic review does not need ethical approval.
Findings of this review will be disseminated via peer-
reviewed journals and conference presentations.
DISCUSSION
This is the protocol for a review and there is no primary
data collection. The systematic review will be published
in a peer-reviewed journal and disseminated electronic-
ally or in print. This review will also benefit patients with
hypertension as they will better understand and accept
the therapy, and change their behaviour regarding the
treatment.
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